8-K: Ardent Health Revises Non-GAAP Earnings Downward

Ardent Health, Inc. is revising its previously reported non-GAAP financial measures, Adjusted EBITDA and Adjusted EBITDAR, for the year ended December 31, 2025, resulting in a substantial decrease in these metrics.

Summary

• Ardent Health, Inc. is filing a Form 8-K to revise its non-GAAP financial measures, specifically Adjusted EBITDA and Adjusted EBITDAR, for the year ended December 31, 2025.
• These revisions are made in response to discussions with the SEC's Division of Corporation Finance and involve removing adjustments related to a change in accounting estimate for accounts receivable collectability and a New Mexico professional liability accrual.
• The aggregate amount removed from these two adjustments for the third quarter of 2025 was $97.7 million.
• As a result, Adjusted EBITDA for the year ended December 31, 2025, decreased from $545.0 million to $447.3 million.
• Adjusted EBITDAR for the same period decreased from $709.3 million to $611.6 million.
• There are no revisions to 2023 or 2024 Adjusted EBITDA or Adjusted EBITDAR, nor to net income for any periods.
• The revisions do not impact the Company's GAAP consolidated financial statements, financial condition, results of operations, or cash flows.
• Updated sections of the 2025 Form 10-K reflecting these revisions are attached as Exhibit 99.1.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the significant reduction in reported non-GAAP earnings, indicating a less favorable financial picture than previously presented.

Negatives

• Reported Adjusted EBITDA for the year ended December 31, 2025, decreased by $97.7 million from $545.0 million to $447.3 million.
• Reported Adjusted EBITDAR for the year ended December 31, 2025, decreased by $97.7 million from $709.3 million to $611.6 million.
• The company is removing previously disclosed adjustments related to accounts receivable collectability and a New Mexico professional liability accrual from its non-GAAP reporting.

Future Outlook

The Company's future periodic reports will reflect the revised presentation, and the next applicable periodic report will include additional enhanced disclosures.

Industry Context

StockSavvy.ai notes that the revision of non-GAAP measures, particularly Adjusted EBITDA and Adjusted EBITDAR, is a sensitive event. Companies often use these metrics to present a more favorable view of performance, and a significant downward revision, especially when prompted by regulatory discussions, can raise concerns about the reliability of prior disclosures and the underlying operational health.

Stakeholder Impact

• Shareholders may view the downward revision of key non-GAAP metrics negatively, potentially impacting investor confidence and stock valuation.
• Analysts and creditors may need to reassess financial performance and covenants based on the revised figures, particularly if they rely heavily on the previously reported non-GAAP measures.

Next Steps

• Future periodic reports will reflect the revised presentation of non-GAAP measures.
• The next applicable periodic report will include additional enhanced disclosures.

Key Dates

Recommendation

The revision of non-GAAP figures downwards, while not impacting GAAP financials, introduces uncertainty and a need for reassessment. It suggests that previously presented performance metrics were less robust than initially communicated. While not a direct indicator of fundamental business decline, it warrants a cautious 'hold' stance until the implications of the revised metrics and future disclosures are fully understood.

Keywords

Non-GAAP, Adjusted EBITDA, Adjusted EBITDAR, Financial Reporting, SEC, Accounting Estimate, Accounts Receivable, Professional Liability